These results indicated that in AML patients the HERC1 gene expression level was significantly lower at diagnosis and not associated with any of the different cytogenetic/genetic group with the interesting exception of the five AML patients harboring the IDH2 R140Q mutation which displayed HERC1 levels indistinguishable from the control group. This evidence concerns the gene IDH2 and acute myeloid leukemia.